Capecitabine-induced hypertriglyceridemia: A rare but clinically relevant treatment-related adverse event

An Uche, Ritika Vankina, Jun Gong, May Cho, James J. Yeh, Phyllis Kim, Kathy Pan

    Research output: Contribution to journalArticlepeer-review

    4 Scopus citations


    Capecitabine-induced hypertriglyceridemia (CIHT) represents an increasingly significant treatment-related adverse event from capecitabine given its potential for both acute complications (acute pancreatitis) and chronic metabolic complications (cardiovascular disease). The incidence of CIHT is relatively rare and the majority of cases thus far reported have been managed with lipid-lowering therapy and/or discontinuation of capecitabine followed by resumption of the drug upon normalization of triglyceride levels. We present among the first U.S. cases of CIHT to be reported in the published literature and highlight management approaches for this rare but clinically relevant adverse event. Further understanding of the mechanisms of CIHT and its long-term adverse effects as well as effective preventive strategies, interventions, and monitoring strategies are prudent given the widespread and often prolonged use of capecitabine-based chemotherapy in gastrointestinal and other cancers.

    Original languageEnglish (US)
    Pages (from-to)1213-1219
    Number of pages7
    JournalJournal of Gastrointestinal Oncology
    Issue number6
    StatePublished - Dec 1 2018


    • Adverse event (AE)
    • Breast cancer
    • Capecitabine
    • Colorectal cancer
    • Hypertriglyceridemia

    ASJC Scopus subject areas

    • Oncology
    • Gastroenterology


    Dive into the research topics of 'Capecitabine-induced hypertriglyceridemia: A rare but clinically relevant treatment-related adverse event'. Together they form a unique fingerprint.

    Cite this